Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Invested Capital: 2012-2025

Historic Return on Invested Capital for Ligand Pharmaceuticals (LGND) over the last 8 years, with Sep 2025 value amounting to 0.02%.

  • Ligand Pharmaceuticals' Return on Invested Capital rose 3.00% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 3.00%. This contributed to the annual value of 0.02% for FY2023, which is N/A change from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Return on Invested Capital stood at 0.02% for Q3 2025, which was up 140.11% from -0.04% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Return on Invested Capital registered a high of 0.10% during Q1 2022, and its lowest value of -0.06% during Q1 2025.
  • Moreover, its 3-year median value for Return on Invested Capital was -0.00% (2023), whereas its average is -0.01%.
  • In the last 5 years, Ligand Pharmaceuticals' Return on Invested Capital dropped by 9bps in 2023 and then rose by 3bps in 2025.
  • Over the past 4 years, Ligand Pharmaceuticals' Return on Invested Capital (Quarterly) stood at 0.05% in 2022, then dropped by 5bps to 0.01% in 2023, then decreased by 1bps to -0.02% in 2024, then increased by 3bps to 0.02% in 2025.
  • Its last three reported values are 0.02% in Q3 2025, -0.04% for Q2 2025, and -0.06% during Q1 2025.